Association of Antibiotic Utilization Measures and Control of Extended-spectrum-lactamases (ESBLs)

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 710 人开始时间: 2004年6月1日最近更新: 2011年4月15日

适应症

试验速览

阶段: 4 期
状态: 已完成
发起方
入组人数: 710
主要终点: Acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months)

To determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection.
To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre and post intervention in the selected medical centers.

•Pregnant and nursing women. Female of childbearing potential without using any birth control methods. Female of childbearing potential using oral contraceptives during study period. (Note: penicillin and beta-lactamase inhibitors may prevent oral contraceptives from working properly, increasing the chance of pregnancy).
•Patients who have the contraindications of using Tazocin (pipercillin/tazobactam)
•Other exclusions apply.

Acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months)

Infection rate of ESBL producing E. coli or K. Pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months)

发起方

Wyeth is now a wholly owned subsidiary of Pfizer

申办方类型

Industry